OptimizeRx (NASDAQ:OPRX) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $8.75, along with a high estimate of $16.00 and a low estimate of $5.00. Observing a downward trend, the current average is 32.69% lower than the prior average price target of $13.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of OptimizeRx's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on OptimizeRx analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know OptimizeRx Better

Unraveling the Financial Story of OptimizeRx

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 30.48% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: OptimizeRx's net margin is impressive, surpassing industry averages. With a net margin of -42.82%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.75%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): OptimizeRx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.4%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: OptimizeRx's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.